Cinacalcet
Side effects
Options:
Hide MedDRA Preferred Terms
MedDRA Preferred Term
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
6
|
Nausea
|
Nausea
|
very common, 31% - 65.5%
|
19%
|
x
|
x
|
x
|
x
|
x
|
x
|
Vomiting
|
Vomiting
|
very common, 27% - 51.7%
|
15%
|
x
|
x
|
x
|
x
|
x
|
x
|
Neoplasm malignant
|
Carcinoma
|
common, 24%
|
|
x
|
x
|
|
|
x
|
x
|
Diarrhoea
|
Diarrhoea
|
postmarketing — 21%
|
20%
|
x
|
x
|
x
|
x
|
x
|
x
|
Paraesthesia
|
Paraesthesia
|
common, 13.8% - 29.4%
|
|
x
|
x
|
x
|
|
x
|
x
|
Asthenia
|
Fatigue
|
7% - 20.7%
|
7%
|
|
|
x
|
|
x
|
x
|
Asthenia
|
common, 7% - 17.2%
|
4%
|
x
|
x
|
x
|
x
|
x
|
x
|
Fatigue
|
Fatigue
|
7% - 20.7%
|
7%
|
|
|
x
|
|
x
|
x
|
Multiple fractures
|
Fracture
|
11.8% - 20.7%
|
|
|
|
|
|
x
|
x
|
Fracture
|
Fracture
|
11.8% - 20.7%
|
|
|
|
|
|
x
|
x
|
Hypercalcaemia
|
Hypercalcaemia
|
11.8% - 20.7%
|
|
|
|
|
|
|
x
|
Dehydration
|
Dehydration
|
0% - 24.1%
|
|
|
|
|
|
x
|
x
|
Myalgia
|
Myalgia
|
postmarketing — 15%
|
14%
|
x
|
x
|
x
|
x
|
x
|
x
|
Musculoskeletal discomfort
|
Myalgia
|
postmarketing — 15%
|
14%
|
x
|
x
|
x
|
x
|
x
|
x
|
Arthralgia
|
5.88% - 17.2%
|
9%
|
|
|
x
|
|
x
|
x
|
Anaemia
|
Anaemia
|
5.88% - 17.2%
|
|
|
|
|
|
x
|
x
|
Arthralgia
|
Arthralgia
|
5.88% - 17.2%
|
9%
|
|
|
x
|
|
x
|
x
|
Constipation
|
Constipation
|
10.3% - 17.6%
|
|
|
|
|
|
x
|
x
|
Depression
|
Depression
|
10.3% - 17.6%
|
|
|
|
|
|
x
|
x
|
Headache
|
Headache
|
0% - 20.7%
|
17%
|
|
|
x
|
|
x
|
x
|
Abdominal pain
|
Abdominal pain
|
12%
|
14%
|
|
|
x
|
|
|
|
Gastrointestinal pain
|
Abdominal pain
|
12%
|
14%
|
|
|
x
|
|
|
|
Pain in extremity
|
Pain in extremity
|
9% - 11.8%
|
10%
|
|
|
x
|
|
x
|
x
|
Upper respiratory tract infection
|
Upper respiratory tract infection
|
10.3% - 12%
|
13%
|
|
|
x
|
|
x
|
x
|
Dizziness
|
Dizziness
|
common, 10%
|
8%
|
x
|
x
|
x
|
x
|
x
|
x
|
Dyspnoea
|
Dyspnoea
|
9%
|
9%
|
|
|
x
|
|
|
|
Dyspepsia
|
Dyspepsia
|
uncommon, 8%
|
8%
|
x
|
x
|
x
|
|
|
|
Body temperature increased
|
Body temperature increased
|
7%
|
10%
|
|
|
x
|
|
|
|
Hypertension
|
Hypertension
|
7%
|
5%
|
|
|
x
|
x
|
x
|
x
|
Oedema peripheral
|
Oedema peripheral
|
7%
|
7%
|
|
|
x
|
|
|
|
Decreased appetite
|
Anorexia
|
common, 5.88% - 20.7%
|
4%
|
x
|
x
|
x
|
x
|
x
|
x
|
Chest pain
|
Chest pain
|
6%
|
4%
|
|
|
x
|
x
|
x
|
x
|
Cough
|
Cough
|
6%
|
7%
|
|
|
x
|
|
|
|
Pruritus
|
Pruritus
|
6%
|
7%
|
|
|
x
|
|
|
|
Thrombosis
|
Thrombosis
|
6%
|
7%
|
|
|
x
|
|
|
|
Infection
|
Infection
|
5%
|
4%
|
|
|
x
|
x
|
x
|
x
|
Hypocalcaemia
|
Hypocalcaemia
|
common
|
|
x
|
x
|
x
|
|
x
|
x
|
Hyperparathyroidism primary
|
Hyperparathyroidism primary
|
common
|
|
x
|
x
|
|
|
|
|
Renal failure chronic
|
Chronic kidney disease
|
common
|
|
x
|
x
|
|
|
|
|
Convulsion
|
Convulsion
|
uncommon
|
|
x
|
x
|
x
|
|
x
|
x
|
Angioedema
|
Angioedema
|
postmarketing
|
|
|
x
|
|
x
|
x
|
x
|
Arrhythmia
|
Arrhythmia
|
postmarketing
|
|
|
|
|
x
|
x
|
x
|
Dermatitis
|
Rash
|
postmarketing, common
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Rash
|
Rash
|
postmarketing, common
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Cardiac failure
|
Cardiac failure
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Hypersensitivity
|
Hypersensitivity
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Hypotension
|
Hypotension
|
postmarketing, 7%
|
12%
|
x
|
x
|
x
|
x
|
x
|
x
|
Urticaria
|
Urticaria
|
postmarketing
|
|
|
x
|
|
x
|
x
|
x
|
Bone disorder
|
Bone disorder
|
|
|
x
|
x
|
|
|
|
|
Gastrointestinal disorder
|
Gastrointestinal disorder
|
|
|
x
|
x
|
|
|
|
|
Gastrointestinal haemorrhage
|
Gastrointestinal haemorrhage
|
|
|
|
|
|
|
x
|
x
|
Immune system disorder
|
Immune system disorder
|
|
|
x
|
x
|
|
|
|
|
Multi-organ failure
|
Multi-organ failure
|
|
|
|
|
|
|
x
|
x
|
Muscle spasms
|
Cramp muscle
|
|
|
|
|
x
|
|
|
|
Nervous system disorder
|
Nervous system disorder
|
|
|
x
|
x
|
|
|
|
|
Tetany
|
Tetany
|
|
|
|
|
x
|
|
|
|
Ventricular arrhythmia
|
Ventricular arrhythmia
|
|
|
|
x
|
|
|
|
|
Malnutrition
|
Malnutrition
|
|
|
x
|
x
|
|
|
|
|
Skin disorder
|
Unspecified disorder of skin and subcutaneous tissue
|
|
|
x
|
x
|
|
|
|
|
Metastatic neoplasm
|
Metastatic carcinoma
|
|
|
|
|
|
|
x
|
x
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 24 |
Source: | EMA |
---|
Side effects: | 27 |
Source: | EMA |
---|
Side effects: | 32 |
Source: | Health Canada |
---|
Side effects: | 17 |
Source: | FDA Structured Product Label |
---|
Side effects: | 34 |
Source: | FDA Structured Product Label |
---|
Side effects: | 35 |
Source: | FDA Structured Product Label |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|